This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

4TEEN4 Pharmaceuticals


At 4TEEN4 we are committed to advancing critical care management to provide therapeutic solutions to patients in critical stages. We are relying on our scientific expertise and technology to drive innovations. Our team is tackling circulatory shock, one of the leading causes of death worldwide and one of the most common reasons for ICU admission. We are developing Procizumab, a first in class antibody therapy and a companion diagnostic (DPP3) to identify and treat patients in circulatory shock. We are currently finishing our GLP toxicology program and aim to enter into clinical development in 2023.